Recruiting studies: Newly Diagnosed Mgmt Unmethylated Glioblastoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Phase 2 · 22 location(s) · Black Diamond Therapeutics, Inc. · NCT07326566 D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Phase 1/Phase 2 · 1 location(s) · Darell Bigner · NCT05734560 DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
Phase 1/Phase 2 · 5 location(s) · University of California, San Francisco · NCT06504381 Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma
Phase 2 · 1 location(s) · Sunnybrook Health Sciences Centre · NCT07476794 WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase 2 · 2 location(s) · Northwestern University · NCT05879250 Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Phase 2 · 1 location(s) · Baptist Health South Florida · NCT06991101 Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma
Phase 1 · 1 location(s) · University of Virginia · NCT07343986 A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
Phase 1/Phase 2 · 3 location(s) · Myosin Therapeutics Inc. · NCT07185880 A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Phase 2/Phase 3 · 63 location(s) · Global Coalition for Adaptive Research · NCT03970447

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.